0 1 [ [ ( 1 4 The the DT 5 9 role role NN 10 12 of of IN 13 27 glucocorticoid glucocorticoid NN 28 37 receptors receptor NNS 38 41 and and CC 42 45 HLA HLA NNP 46 54 antigens antigen NNS 55 57 in in IN 58 61 the the DT 62 74 pathogenesis pathogenesis NN 75 77 of of IN 78 85 Cushing cushing NN 85 87 ’s 's POS 88 96 syndrome syndrome NN 96 97 ] ] ) 99 110 Lymphocytic lymphocytic JJ 111 117 levels level NNS 118 120 of of IN 121 135 glucocorticoid glucocorticoid NN 136 145 receptors receptor NNS 146 150 were be VBD 151 160 evaluated evaluate VBN 161 163 in in IN 164 167 114 114 CD 168 176 patients patient NNS 177 186 suffering suffer VBG 187 191 from from IN 192 206 Icenko-Cushing icenko-cushing NN 206 208 ’s 's POS 209 217 syndrome syndrome NN 217 218 . . . 219 228 Incidence incidence NN 229 231 of of IN 232 235 HLA HLA NNP 236 244 antigens antigen NNS 245 248 was be VBD 249 259 determined determine VBN 260 262 in in IN 263 265 94 94 CD 266 268 of of IN 269 273 them them PRP 273 274 . . . 275 276 A a DT 277 288 significant significant JJ 289 293 rise rise NN 294 296 of of IN 297 300 A10 A10 NNP 301 304 and and CC 305 308 B27 b27 NN 309 316 antigen antigen NN 317 326 incidence incidence NN 327 335 compared compare VBN 336 338 to to TO 339 343 that that DT 344 346 in in IN 347 353 normal normal JJ 354 362 subjects subject NNS 363 369 allows allow VBZ 370 375 these these DT 376 384 antigens antigen NNS 385 387 to to TO 388 390 be be VB 391 401 considered consider VBN 402 409 genetic genetic JJ 410 417 markers marker NNS 418 420 of of IN 421 435 Icenko-Cushing icenko-cushing NN 435 437 ’s 's POS 438 446 syndrome syndrome NN 446 447 . . . 448 451 The the DT 452 458 levels level NNS 459 461 of of IN 462 476 glucocorticoid glucocorticoid NN 477 486 receptors receptor NNS 487 489 in in IN 490 501 lymphocytes lymphocyte NNS 502 504 of of IN 505 508 the the DT 509 517 patients patient NNS 518 521 are be VBP 522 527 lower low JJR 528 532 than than IN 533 535 in in IN 536 542 normal normal JJ 543 551 subjects subject NNS 552 556 both both CC 557 559 in in IN 560 563 the the DT 564 570 active active JJ 571 576 stage stage NN 577 579 of of IN 580 583 the the DT 584 591 disease disease NN 592 595 and and CC 596 605 following follow VBG 606 615 bilateral bilateral JJ 616 621 total total JJ 622 635 adrenalectomy adrenalectomy NN 635 636 . . . 637 640 The the DT 641 649 patients patient NNS 650 658 carrying carry VBG 659 662 B27 b27 NN 663 670 antigen antigen NN 671 674 had have VBD 675 686 lymphocytic lymphocytic JJ 687 695 receptor receptor NN 696 710 concentrations concentration NNS 711 716 under under IN 717 720 the the DT 721 727 levels level NNS 728 730 of of IN 731 735 such such JJ 736 738 in in IN 739 747 patients patient NNS 748 752 free free JJ 753 755 of of IN 756 759 the the DT 760 767 antigen antigen NN 768 776 carriage carriage NN 776 777 . . . 778 785 Antigen antigen NN 786 789 B27 b27 NN 790 795 seems seem VBZ 796 798 to to TO 799 801 be be VB 802 803 a a DT 804 809 cause cause NN 810 812 of of IN 813 818 lower low JJR 819 825 levels level NNS 826 828 of of IN 829 843 glucocorticoid glucocorticoid NN 844 853 receptors receptor NNS 854 856 in in IN 857 862 blood blood NN 863 874 lymphocytes lymphocyte NNS 874 875 . . .